Steven G DuBois

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143 0106, USA
    Cancer Chemother Pharmacol 69:1021-7. 2012
  2. ncbi Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data
    Steven G DuBois
    Department of Pediatrics, University of California at San Francisco School of Medicine, San Francisco, California 94143 0106, USA
    Cancer 116:749-57. 2010
  3. ncbi Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow
    Steven G DuBois
    Department of Pediatrics, University of California San Francisco School of Medicine, San Francisco, CA 94143 0106, USA
    Pediatr Blood Cancer 54:13-8. 2010
  4. ncbi Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, CA 94143 0106, USA
    Clin Cancer Res 17:5113-22. 2011
  5. ncbi Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143 0106, USA
    Pediatr Blood Cancer 52:324-7. 2009
  6. ncbi Late recurrence of ewing sarcoma during pregnancy: a report of 2 cases
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco, CA 94143 0106, USA
    J Pediatr Hematol Oncol 30:716-8. 2008
  7. ncbi Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco, California, USA
    Pediatr Blood Cancer 51:589-92. 2008
  8. ncbi Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA
    Pediatr Blood Cancer 58:181-4. 2012
  9. ncbi Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms
    Sabine Mueller
    Department of Neurology, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143 0106, USA
    Cancer Lett 306:223-9. 2011
  10. ncbi Prognostic Value of the Stage 4S Metastatic Pattern and Tumor Biology in Patients With Metastatic Neuroblastoma Diagnosed Between Birth and 18 Months of Age
    Denah R Taggart
    Department of Pediatrics, UCSF School of Medicine, 505 Parnassus Ave, Box 0106, San Francisco, CA 94143 0106
    J Clin Oncol 29:4358-64. 2011

Collaborators

Detail Information

Publications20

  1. ncbi Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143 0106, USA
    Cancer Chemother Pharmacol 69:1021-7. 2012
    ..A pediatric phase I study of sunitinib capsules identified the maximum tolerated dose as 15 mg/m(2)/day. This study was conducted to evaluate sunitinib given as a powder formulation...
  2. ncbi Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data
    Steven G DuBois
    Department of Pediatrics, University of California at San Francisco School of Medicine, San Francisco, California 94143 0106, USA
    Cancer 116:749-57. 2010
    ..For the current review, the authors summarized the available data supporting this approach...
  3. ncbi Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow
    Steven G DuBois
    Department of Pediatrics, University of California San Francisco School of Medicine, San Francisco, CA 94143 0106, USA
    Pediatr Blood Cancer 54:13-8. 2010
    ..A new method for detecting circulating Ewing sarcoma cells using flow cytometry is described. This strategy exploits the nearly universal expression of CD99 and the lack of expression of CD45 by Ewing sarcoma cells...
  4. ncbi Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, CA 94143 0106, USA
    Clin Cancer Res 17:5113-22. 2011
    ..The purpose of this study was to determine the recommended phase 2 dose, pharmacokinetics, pharmacodynamic effects, and preliminary antitumor activity of sunitinib in a pediatric population...
  5. ncbi Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143 0106, USA
    Pediatr Blood Cancer 52:324-7. 2009
    ..The purpose of this phase II clinical trial was to estimate the response rate of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma...
  6. ncbi Late recurrence of ewing sarcoma during pregnancy: a report of 2 cases
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco, CA 94143 0106, USA
    J Pediatr Hematol Oncol 30:716-8. 2008
    ..These receptors were not detected by immunohistochemistry. Increased medical surveillance during pregnancy may have resulted in ascertainment of recurrence in these 2 patients...
  7. ncbi Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco, California, USA
    Pediatr Blood Cancer 51:589-92. 2008
    ..We aimed to describe the incidence, clinical characteristics, and outcome of patients with lung metastasis at initial diagnosis using a large international database...
  8. ncbi Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA
    Pediatr Blood Cancer 58:181-4. 2012
    ..Circulating endothelial cells (CECs) have been detected at increased numbers in patients with solid cancers. CECs have not been systematically evaluated in patients with osteosarcoma...
  9. ncbi Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms
    Sabine Mueller
    Department of Neurology, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143 0106, USA
    Cancer Lett 306:223-9. 2011
    ..DNA repair enzyme Ku-86 was reduced in several neuroblastoma cells treated with vorinostat. Thus, vorinostat potentiates anti-neoplastic effects of radiation in neuroblastoma possibly due to down-regulation of DNA repair enzyme Ku-86...
  10. ncbi Prognostic Value of the Stage 4S Metastatic Pattern and Tumor Biology in Patients With Metastatic Neuroblastoma Diagnosed Between Birth and 18 Months of Age
    Denah R Taggart
    Department of Pediatrics, UCSF School of Medicine, 505 Parnassus Ave, Box 0106, San Francisco, CA 94143 0106
    J Clin Oncol 29:4358-64. 2011
    ..CONCLUSION Tumor biology is more critical than age or metastatic pattern for prognosis of patients age younger than 18 months with metastatic neuroblastoma and should be considered for risk stratification...
  11. ncbi Osteosarcoma in children 5 years of age or younger at initial diagnosis
    Jennifer Worch
    Department of Pediatrics and Department of Epidemiology Biostatistics, University of California, San Francisco School of Medicine, San Francisco, California, USA
    Pediatr Blood Cancer 55:285-9. 2010
    ..Since osteosarcoma is extremely rare in children < or =5 years of age, we sought to investigate if tumor characteristics, treatment strategies, and outcomes differ compared to older patients...
  12. ncbi Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults
    Alexei L Polishchuk
    Department of Pediatrics, University of California at San Francisco School of Medicine and UCSF Benioff Children s Hospital, San Francisco, California, USA
    Cancer 117:4286-93. 2011
    ..The objective of the current study was to characterize the toxicity and activity of this therapy in older patients...
  13. ncbi Clinical features and outcomes in patients with extraskeletal Ewing sarcoma
    Mark A Applebaum
    Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, California, USA
    Cancer 117:3027-32. 2011
    ..The purpose of this study was to investigate whether patient characteristics, treatment strategies, and outcomes differ between skeletal Ewing sarcoma and extraskeletal Ewing sarcoma (EES)...
  14. ncbi Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation
    Jennifer Worch
    Department of Pediatrics, University of California, San Francisco, School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143 0106, USA
    Cancer Epidemiol Biomarkers Prev 20:449-53. 2011
    ..The incidence of Ewing sarcoma varies by race, with very low rates among persons of African and East Asian ancestry. The incidence by race of other mesenchymal tumors that also harbor EWSR1 translocations has not been studied...
  15. ncbi Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, Box 0106, San Francisco, CA 94143 0106, USA
    Nucl Med Biol 35:S35-48. 2008
    ..Neuroblastoma is the most common pediatric extracranial solid cancer. This tumor is characterized by metaiodobenzylguanidine (MIBG) avidity in 90% of cases, prompting the use of radiolabeled MIBG for targeted radiotherapy in these tumors...
  16. ncbi Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma
    Steven G DuBois
    University of California San Francisco UCSF School of Medicine, San Francisco, CA, USA
    Nat Rev Clin Oncol 6:251-3. 2009
    ..Subgroup analysis suggested that patients with large, localized tumors benefited from the addition of etoposide, whereas patients with metastases did not...
  17. ncbi Ethnic and racial differences in patients with Ewing sarcoma
    Jennifer Worch
    Department of Pediatrics, University of California at San Francisco School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143 0106, USA
    Cancer 116:983-8. 2010
    ..The goal of the current study was to evaluate racial and ethnic differences in presentation and overall survival (OS) among patients diagnosed with ES before age 40 years...
  18. ncbi Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA
    J Clin Oncol 22:2452-60. 2004
    ..Bone marrow tumor at time of treatment was the most useful predictor of hematotoxicity, whereas whole-body radiation dose was the most useful predictor of failure to recover platelets after AHSCT...
  19. ncbi Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy
    Siavash Jabbari
    Department of Radiation Oncology, University of California, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 75:177-82. 2009
    ..To evaluate the role of radiation therapy (RT) as a component of multimodality therapy for pediatric desmoids...
  20. ncbi Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems
    Swati S More
    Departments of Bioengineering and Therapeutic Sciences, UCSF School of Medicine and UCSF Benioff Children s Hospital, San Francisco, California 94158, USA
    Clin Cancer Res 17:2339-49. 2011
    ....